Xender to distribute 10,000 CyberCare systems

Article

Xender to distribute 10,000 CyberCare systemsXender Corporation, a Taiwanese electronic instruments manufacturer, has signed a licensing agreement with CyberCare, a technology-based health management company, to manufacture, sell, and distribute

Xender to distribute 10,000 CyberCare systems

Xender Corporation, a Taiwanese electronic instruments manufacturer, has signed a licensing agreement with CyberCare, a technology-based health management company, to manufacture, sell, and distribute 10,000 CyberCare Electronic HouseCall systems over the next three years. Under terms of the deal, Xender will pay CyberCare a $500 per unit royalty fee to install, operate, and maintain the communications network in Taiwan and will receive a recurring network fee of $200 per month per installed unit.

Xender claims to have established relationships with more than 300 medical facilities in Taiwan and expects these customers to purchase the Electronic HouseCall system to enhance care for their chronically ill patients. The Electronic HouseCall is an Internet-based system for remote monitoring of patients.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.